¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"graft occlusion"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • onlay graft
    ¾ñ±âÀ̽Ä, ÁßøÀ̽Ä
  • orthotopic graft
    °°ÀºÀÚ¸®À̽Ä
  • osteoperiosteal graft
    »À»À¸·À̽Ä, °ñ°ñ¸·À̽Ä
  • pinch graft
    ¼ÒÆíÀ̽Ä(¼ú)
  • prosthetic material graft
    º¸Çü¹°À̽Ä
  • partial thickness graft
    ºÎºÐÃþÀÌ½ÄÆí, ºÎºÐÃþÀ̽ļú
  • perichondral cutaneous graft
    ¿¬°ñ¸·ÇǺÎÀ̽Ä
  • periosteal graft
    »À¸·À̽Ä, °ñ¸·À̽Ä
  • rope graft
    ¸Á»óÀÌ½ÄÆí
  • split rib graft
    ºÐÇÒ°¥ºñÀ̽Ä, ºÐÇÒ´Á°ñÀ̽Ä
  • split-thickness skin graft
    ºÎºÐÃþÇǺÎÀ̽Ä
  • sponge graft
    ½ºÆÝÁöÀ̽Ä
  • spreader graft
    ÆîħÀ̽Ä
  • strip composite scalp graft
    ¶ìº¹ÇÕµÎÇÇÀ̽Ä
  • septal cartilage graft
    ÄÚÁß°Ý¿¬°ñÀ̽Ä, ºñÁß°Ý¿¬°ñÀ̽Ä
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • partial thickness graft
    ºÎºÐÃþÀÌ½ÄÆí, ºÎºÐÃþÀ̽ļú
  • perichondral cutaneous graft
    ¿¬°ñ¸·ÇǺÎÀ̽Ä
  • periosteal graft
    »À¸·À̽Ä, °ñ¸·À̽Ä
  • pinch graft
    ¼ÒÆíÀ̽ļú
  • prosthetic material graft
    º¸Ã¶¹°À̽Ä
  • rope graft
    ¸Á»óÀÌ½ÄÆí
  • septal cartilage graft
    ÄÚÁß°Ý¿¬°ñÀ̽Ä, ºñÁß°Ý¿¬°ñÀ̽Ä
  • sleeve graft
    ¼ö»óÀ̽Ä, ¼Ò¸ÅÀ̽Ä
  • split rib graft
    ºÐÇÒ°¥ºñÀ̽Ä
  • split-skin graft
    ºÎºÐÃþÇǺÎÀ̽Ä
  • sponge graft
    ½ºÆùÁöÀ̽Ä
  • spreader graft
    ÆîħÀ̽Ä
  • strip composite scalp graft
    ¶ìº¹ÇÕµÎÇÇÀ̽Ä
  • tube graft
    °ü»óÀ̽Ä, °ü»óÀÌ½ÄÆí
  • skin graft inlay
    ¼Ó³Ö±âÇǺÎÀ̽Ä, °¨ÀÔÇǺÎÀ̽Ä
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • bridging graft
    ±³·®À̽Ä(±³¾çÀ̽Ä).
  • bypass graft
    ȸ·ÎÁ¶¼º¼ú(ȸ·ÎÁ¶¼º¼ú), ¿ìȸ·ÎÀ̽Ä<Á¶¼º>¼ú.
  • bypass graft
    ¿ìȸ·Î À̽Ä(Á¶¼º)¼ú(éæüÞÖØì¹ãÕ[ðãà÷]âú).
  • cartilage graft
    ¿¬°ñÀ̽Ä
  • chorioallantoic graft
    À¶¸ð¿ä¸·À̽Ä(ëÖÙ¾èñدì¹ãÕ).
  • collagen graft
    ±³¿øÁúÀ̽Ä
  • composite graft
    º¹ÇÕÁ¶Á÷À̽Ä.
  • corneal graft
    °¢¸·ÀÌ½ÄÆí(¡­ì¹ãÖ).
  • coronary artery bypass graft
    °ü»óµ¿¸Æ¿ìȸ·Î¼úÀ̽Ä(¼ú).
  • coronary artery bypass graft
    °ü»óµ¿¸Æ¿ìȸ·Î¼úÀ̽Ä(¼ú).
  • cultured keratinocyte graft
    ¹è¾ç°¢Áú¼¼Æ÷ À̽Ä
  • dermic graft
    ½ÄÇÇ(½ÄÇÇ).
  • dermis graft
    ÁøÇÇÀ̽Ä
  • double-end graft
    ½Ö´ÜÀ̽Ä.
  • dural graft
    °æ¸·À̽Ä(°æ¸·À̽Ä).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 6
PAO peak acid output; peripheral airway obstruction; plasma amine oxidase; polyamine oxidase; pulmonary ...
PAo airway opening pressure; ascending aortic pressure; pulmonary artery occlusion pressure
PAOP pulmonary artery occlusion pressure
PICSO pressure-controlled intermittent coronary sinus occlusion
SAO small airway obstruction; splanchnic artery occlusion; subvalvular aortic obstruction
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 6
CABG CORONARY ARTERY BYPASS GRAFT
cGVHD Chronic graft versus host disease
cGVHD Chronic graft-vs.-host disease
CABG Coronary Artery Bypass Graft surgery
DGF Delayed graft function
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • opposite occlusion
    ÇÏ¾Ç Àüµ¹, ÇÏ¾Ç Àüµ¹Áõ
  • optimum functional occlusion
    ±â´ÉÀû ÃÖÀû ±³ÇÕ
  • pathogenic occlusion
    º´¿ø¼º ±³ÇÕ
    ÀúÀÛ°è¿¡ º´ÀûÀÎ º¯È­¸¦ À¯¹ßÇÒ ¼ö ÀÖ´Â ±³ÇÕ °ü°è.
  • percutaneous transhepatic variceal occlusion
    °æÇÇ°æ °£Á¤¸Æ·ù Æó»ö¼ú
  • physilogic normal occlusion
    »ý¸®Àû Á¤»ó ±³ÇÕ
  • plane of occlusion
    ±³ÇÕ Æò¸é
    Ä¡¾ÆÀÇ Àý´Ü¸é°ú ±³Çո鿡 Çü¼ºµÇ´Â Æò±Õ¸é.
  • posterior occlusion
    ÈÄÃø ±³ÇÕ
  • primary traumatic occlusion
    ÀÏÂ÷Àû ¿Ü»ó¼º ±³ÇÕ, ¿ø¹ß¼º ¿Ü»ó¼º ±³ÇÕ, ÀÏÂ÷ÀûÀÎ ¿Ü»ó¼º ±³ÇÕ
  • progenia reversed occlusion
    ÇÏ¾Ç Àüµ¹, ÇÏ¾Ç Àüµ¹Áõ
  • protrusive occlusion
    Àüµ¹ ±³ÇÕ, Àü¹æ ±³ÇÕ
    ÇϾǰñÀ» ³»¹Ð¾úÀ» ¶§ÀÇ »óÇÏ Ä¡¾ÆÀÇ ±³ÇÕ °ü°è.
  • renal arterial occlusion
    ½Åµ¿¸Æ Æó»ö
  • retrusive occlusion
    ÈÄÀü ±³ÇÕ
  • reverse occlusion
    ¹Ý´ë ±³ÇÕ
  • reversed occlusion
    ¹Ý´ë ±³ÇÕ
  • sagittal curve of occlusion
    ±³ÇÕÀÇ ½Ã»ó ¸¸°î
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
graft enhancement, immunologic The induction of prolonged survival and growth of allografts of either tumours or normal tissues which would ordinarily be rejected. It may be induced passively by introducing graft-specific antibodies from previously immunised donors, which bind to the graft's surface antigens, masking them from recognition by T-cells; or actively by prior immunization of the recipient with graft antigens which evoke specific antibodies and form antigen-antibody complexes which bind to the antigen receptor sites of the T-cells and block their cytotoxic activity.
(12 Dec 1998)
graft rejection <haematology, immunology> When donated bone marrow infused during a bone marrow transplant is rejected by the patients body or does not take.
(16 Dec 1997)
graft survival <haematology> The survival of a graft in a host, the factors responsible for the survival and the changes occurring within the graft during growth in the host.
(12 Dec 1998)
graft-versus-host disease <haematology> A common and serious, complication of bone marrow transplantation where there is a reaction of donated bone marrow against a patient's own tissue.
When donor lymphocytes or a graft containing lymphocytes that are immunologically competent are given to a patient that has low immunological competence, an incompatibility reaction can result. This is due to antibodies from the donor against antigens in the host. This is due to mismatch of MHC Class I antigens and can produce lymphocyte clones that will react by a variety of processes against the host and cause damage.
The clinical condition can be fatal and is due to the donor's immune cells recognising the host cells as foreign.
The clinical entity characterised by anorexia, diarrhoea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the graft-versus-host reaction. It can occur in either chronic or acute forms and is treatable by immunosuppressive drugs.
Seen most commonly following bone marrow transplantation, acute disease is seen after 5-40 days and chronic disease weeks to months after transplantation, affecting, principally, the gastrointestinal tract, liver, and skin.
Radiological appearances of the gastrointestinal tract include; thickened wall, mucosal folds thickened or effaced, increased secretions most likely to be rapid transit of GI tract, mass most likely to be focal oedema, fibrosis, hallmark: diffuse, uniform thickening of small bowel.
Synonym: GVH disease.
Acronym: GVHD
(20 Sep 2002)
graft-versus-host reaction <haematology> A common and serious, complication of bone marrow transplantation where there is a reaction of donated bone marrow against a patient's own tissue.
When donor lymphocytes or a graft containing lymphocytes that are immunologically competent are given to a patient that has low immunological competence, an incompatibility reaction can result. This is due to antibodies from the donor against antigens in the host. This is due to mismatch of MHC Class I antigens and can produce lymphocyte clones that will react by a variety of processes against the host and cause damage.
The clinical condition can be fatal and is due to the donor's immune cells recognising the host cells as foreign.
The clinical entity characterised by anorexia, diarrhoea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the graft-versus-host reaction. It can occur in either chronic or acute forms and is treatable by immunosuppressive drugs.
Seen most commonly following bone marrow transplantation, acute disease is seen after 5-40 days and chronic disease weeks to months after transplantation, affecting, principally, the gastrointestinal tract, liver, and skin.
Radiological appearances of the gastrointestinal tract include; thickened wall, mucosal folds thickened or effaced, increased secretions most likely to be rapid transit of GI tract, mass most likely to be focal oedema, fibrosis, hallmark: diffuse, uniform thickening of small bowel.
Synonym: GVH disease.
Acronym: GVHD
(20 Sep 2002)
graft-versus-host response <haematology> A common and serious, complication of bone marrow transplantation where there is a reaction of donated bone marrow against a patient's own tissue.
When donor lymphocytes or a graft containing lymphocytes that are immunologically competent are given to a patient that has low immunological competence, an incompatibility reaction can result. This is due to antibodies from the donor against antigens in the host. This is due to mismatch of MHC Class I antigens and can produce lymphocyte clones that will react by a variety of processes against the host and cause damage.
The clinical condition can be fatal and is due to the donor's immune cells recognising the host cells as foreign.
The clinical entity characterised by anorexia, diarrhoea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the graft-versus-host reaction. It can occur in either chronic or acute forms and is treatable by immunosuppressive drugs.
Seen most commonly following bone marrow transplantation, acute disease is seen after 5-40 days and chronic disease weeks to months after transplantation, affecting, principally, the gastrointestinal tract, liver, and skin.
Radiological appearances of the gastrointestinal tract include; thickened wall, mucosal folds thickened or effaced, increased secretions most likely to be rapid transit of GI tract, mass most likely to be focal oedema, fibrosis, hallmark: diffuse, uniform thickening of small bowel.
Synonym: GVH disease.
Acronym: GVHD
(20 Sep 2002)
mesh graft A skin graft in which multiple slits have been made, so it can be stretched to cover a large area.
Synonym: mesh graft.
(05 Mar 2000)
periosteal graft A graft of periosteum, usually placed on bare bone.
(05 Mar 2000)
chip graft A graft utilizing small pieces of cartilage or bone which is packed into a bone defect.
(05 Mar 2000)
chorioallantoic graft Transplanting of living material to the chorioallantoic membrane of the embryonic chick.
(05 Mar 2000)
Phemister graft An autogenous onlay bone graft used in treating delayed union of fractures.
(05 Mar 2000)
pinch graft Small bits of skin, of partial or full thickness, removed from a healthy area and seeded in a site to be covered.
Synonym: Reverdin graft.
(05 Mar 2000)
white graft Rejection of a skin allograft so acute that vascularization never occurs.
(05 Mar 2000)
composite graft A graft composed of several structures, such as skin and cartilage or a full-thickness segment of the ear.
(05 Mar 2000)
mucosal graft A graft of mucous membrane, usually the full-thickness of the lining of the cheek or lower lip.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 6
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 6
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 6
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 6
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 6
ÅëÇÕ°Ë»ö ¿Ï·á